Product Name: Recombinant Human Fibroblast Growth Factor-acidic (rh-aFGF)
Catalog Number: NRPA15S
Specifications: 10 μg, 100 μg, 1 mg, 10 mg
Formulation: Lyophilized from 10mM PBS (1mM Na2HPO4, 9mM NaH2PO4, 150mM NaCl, pH6.0)
Mol. Wt.: 16.0kDa
Theory pI: 7.73
Resources: Escherichia coli (E. coli)
Purity: ≥95% by SDS-PAGE analysis
Storage Condition: -20 oC
Storage Duration: 3 years
Biological Activity: The EC50, calculated by the dose-dependant proliferation of mouse BALB/c 3T3 cells is less than 0.5 ng/ml, corresponding to a specific activity of ≥2×106 units/mg protein.
Packing：In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Application：This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.
Stability & storage conditions：
Use a manual defrost freezer。No activity loss was observed after storage at:
4-8°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
Fibroblast Growth Factor-acidic, aFGF is a protein that in humans is encoded by the FGF1 gene. The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF acidic is a potent growth factor for fibroblasts and endothelial cells. FGF acidic is involved in wound repair, angiogenesis, and development. FGF acidic is secreted from cells via an endoplasmic reticulum/Golgi independent mechanism. The ability of FGF acidic to bind to heparin sulfate is required for its ability to interact with FGF receptors and induce signaling. There are four distinct FGF receptors and each has multiple splice variants. FGF acidic binds with high affinity to many, but not all, FGFRs. Signaling cascades activated through FGF basic binding to FGFR include the ras-raf-MAPK, PLCy/PKC, and PI3K/Akt pathways.
? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ??
M：Protein marker standard? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?rh-aFGF stimulate BALB/c 3T3 Cell proliferation test
For research use only!
Proteoglycan/glycosaminoglycan and collagen content in the arterial wall of patients with end-stage renal disease - new indicators for vascular disease
Author : Batko Krzysztof K, Krzanowski Marcin M, Gajda Mariusz M, Dumnicka Paulina P, Pietrzycka Agata A, Fedak Danuta D, Woziwodzka Karolina K, Go?asa Paulina P, Ku?niewski Marek M
Journal : 2019-10-15 DOI : 10.1002/smll.201802403
Abstract : + Cardiovascular (CV) comorbidity is high in chronic kidney disease, particularly in end-stage renal disease (ESRD).
Rifampicin, Not Vitamin E, Suppresses Parenteral Nutrition Associated Liver Disease Development through Pregnane X Receptor Pathway in Piglets
Author : Guthrie Gregory G, Stoll Barbara B, Chacko Shaji S, Lauridsen Charlotte C, Plat Jogchum J
Journal : Am. J. Physiol. Gastrointest. Liver Physiol. 2019-10-11 DOI : 10.1002/smll.201802403
Abstract : + Infants receiving long-term parenteral nutrition (PN) develop PN associated liver disease (PNALD).
Probiotic LGG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice
Author : Liu Yunhuan Y, Chen Kefei K, Li Fengyuan F, Gu Zelin Z, Liu Qi Q, He Liqing L, Shao Tuo T, Song Qing Q, Zhu Fenxia F
Journal : Hepatology 2019-09-30 DOI : 10.1002/smll.201802403
Abstract : + Cholestatic liver disease is characterized by gut dysbiosis and excessive toxic hepatic bile acids (BAs).